stockportfolio.pro
Stocks / BBIO vs EXEL
BBIO vs EXEL
BridgeBio Pharma, Inc. and Exelixis, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BridgeBio Pharma, Inc. (BBIO) | Exelixis, Inc. (EXEL) | |
|---|---|---|
| Market cap | $13.3B | $13.4B |
| Revenue (latest FY) | $502.08M | $2.32B |
| Net income (latest FY) | $-724.93M | $782.57M |
| Revenue growth (5y CAGR) | 127.4% | 18.6% |
| Net margin | -144.4% | 33.7% |
| Return on equity | 34.7% | 36.2% |
| P/E ratio | — | 17.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BBIO — free Open EXEL — freeFrequently asked questions
Which is bigger, BBIO or EXEL?
Exelixis, Inc. is larger by market capitalization — $13.4B versus $13.3B.
Which grows faster, BBIO or EXEL?
Over the last five fiscal years, BridgeBio Pharma, Inc. grew revenue faster — 127.4%/yr versus 18.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.